22 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results…
Race Oncology Limited (“Race”) is pleased to share interim results from our collaborative preclinical melanoma research program with the University of Newcastle (ASX Announcement: 19 Mar 2021). Eminent melanoma researchers, Professor Xu Dong Zhang and Associate Professor Lei Jin, are leading the project.
This program is exploring the use of Zantrene® (bisantrene dihydrochloride) as a novel potential treatment for melanoma using cellular and mouse models. The aim is to identify drug combinations and melanoma subtypes that show improved treatment responses, with a focus on treatment-resistant melanomas.
Zantrene has been identified as a potent targeted inhibitor of the Fat Mass and Obesity associated protein (FTO)1. Previous studies have observed that FTO is over-produced in approximately 50% of metastatic melanomas2 and that inhibition of FTO can overcome PD-1 immune checkpoint resistance in mouse melanoma models2,3. PD-1 immune checkpoint inhibitors have emerged as a front-line treatment for many types of cancer, including melanoma. While there have been major advances in melanoma treatments in recent decades, the five-year survival rate for advanced melanoma remains low4.
“These interim results are highly encouraging and support our clinical plans for Zantrene, with the correlation between FTO overexpression and sensitivity to Zantrene suggesting a strong anti-FTO therapeutic opportunity. The high sensitivity of many of the melanoma cell lines to Zantrene as a single agent at concentrations well below chemotherapeutic doses is unexpected and may offer new treatment options for melanoma patients.”
Race CSO Dr Daniel Tillett
“While challenged by COVID 19 related shutdowns we appreciate the encouraging and continued work from the team at the University of Newcastle. Zantrene continues to positively surprise us – we are very pleased with these early results. Melanoma remains a difficult cancer to treat, and one that’s of particular relevance to the Australian community, so as we continue with this work, we look forward to learning more about our potential to offer new treatment options to patients.”
Race CEO & MD Phillip Lynch
Melanoma is unresponsive to existing anthracyclines, yet Zantrene showed significant historical in vitro activity against fresh human melanoma samples taken from patients in human tumor cloning assays5,6. In a subsequent Phase I trial of Zantrene administered weekly, a patient with metastatic melanoma achieved a complete response lasting 6 months7. This weekly dosing schedule would likely have resulted in sustained inhibition of FTO due to the long time Zantrene remains in the human body.
Despite these early successes, four subsequent Phase 2 studies of Zantrene in 100 melanoma patients used much longer dosing intervals of once every three or 4 weeks and did not achieve the same levels of clinical response, possibly due to limited, transient inhibition of FTO8-11. Seventeen patients (1/16, 2/16, 0/17, 14/51) achieved disease stabilization, but no further complete responses were observed.
In light of the recent discovery that Zantrene is a potent inhibitor of the m6A RNA demethylase FTO1 and that FTO is frequently overexpressed in metastatic melanoma2, Race sought to explore the use of Zantrene for treating melanoma, both as a single agent and in combination with other standard of care drugs. This research will also help inform the dose regimen to be explored in future clinical trials.
Zantrene proved to be highly effective at killing melanoma cell lines, with 60% (15 of 25) displaying IC50 values below 100 nM concentrations (Table 1). This was seen with cell lines derived from both primary and metastatic melanoma patients. Interestingly, six of the 25 cell lines showed extreme sensitivity to Zantrene (IC50 values under 40 nM), suggesting that Zantrene may provide an effective single agent treatment for some patients.
The untransformed melanocyte cell line (normal) was highly resistant to cell killing by Zantrene, as were some of the melanoma cell lines (Table 1). The molecular mechanisms underlying this resistance to Zantrene remain to be determined.
Cell Line | IC50 (nM) |
HEMm-MP | 1403 |
MEL-BP | 1003 |
SK-MEL-110 | 1002 |
SK-Mel-28 | 515 |
Mel-JD | 335 |
MM426 | 312 |
Mel-RM | 178 |
Mel-RMu | 167 |
Mel-CV | 115 |
Mel-FH | 102 |
MM200 | 96 |
A375 | 87 |
MM170-5 | 85 |
MM283 | 79 |
ME1007 | 78 |
SK-MEL-37 | 75 |
IgR3 | 72 |
SK-MEL-13 | 67 |
ME4405 | 53 |
MEL-BE | 39 |
MV3 | 39 |
MEL-EH | 37 |
MEL-JR | 30 |
MEL-KD | 28 |
MM962 | 23 |
Zantrene sensitivity did not show any correlation to either BRAF or NRAS mutational status, with individual mutant and wild type cell lines displaying a wide range of IC50 values. This result suggests that Zantrene® may show utility in patients resistant to BRAF and NRAS inhibitors.
Cell Line | IC50 (nM) | BRAF | NRAS |
HEMn-MP | 1403 | Wild | Wild |
SK-Mel-28 | 515 | Mutant | Wild |
Mel-JD | 335 | Wild | Mutant |
Mel-RM | 178 | Wild | Mutant |
Mel-Rmu | 167 | Mutant | Wild |
Mel-CV | 115 | Mutant | Wild |
Mel-FH | 102 | Wild | Wild |
ME1007 | 78 | Wild | Wild |
MM200 | 96 | Mutant | Wild |
IgR3 | 72 | Mutant | Wild |
ME4405 | 53 | Wild | Mutant |
Zantrene sensitivity was correlated with FTO protein overexpression levels (Figure 1 and Table 3).
The eight most Zantrene-resistant cell lines (i.e. those with an IC50 values greater than 100 nM) had a median FTO expression level 1.4 fold higher that of the untransformed (normal) melanocyte cell line, HEMn-MP.
In contrast, the 15 most sensitive melanoma cell lines had a median increase in FTO protein levels of 2.5 fold. The five most sensitive cell lines (i.e. those with IC50 values below 40 nM) had an average increase in FTO protein levels 3.8 fold higher (Table 3).
Cell Line | FTO Level |
HEMm-MP | 1.0 |
Mel-BP | 2.2 |
SK-MEL-110 | 5.0 |
SK-Mel-28 | 1.0 |
Mel-JD | 1.3 |
MM426 | 2.8 |
Mel-RM | 1.6 |
Mel-RMu | 1.4 |
Mel-CV | 1.4 |
Mel-FH | 2.6 |
MM200 | 1.1 |
70W | 1.9 |
MM170-5 | 3.5 |
MM283 | 2.4 |
ME1007 | 1.3 |
SK-MEL-37 | 2.4 |
IGR3 | 2.7 |
SK-MEL-13 | 4.4 |
ME4405 | 2.0 |
Mel-BE | 1.7 |
MV3 | 5.8 |
Mel-EH | 2.2 |
Mel-JR | 3.6 |
Mel-KD | 2.5 |
MM962 | 5.0 |
The SK-MEL-10 was an exception to the trend of high FTO overexpression being associated with high sensitivity to Zantrene. This cell line had an IC50 value over 1000 nM while displaying an FTO expression level 5 fold that of HEMn-MP. The reason for this resistance is unknown, but may be linked to high expression of drug efflux pumps like MDR1 that are known to reduce the intracellular concentration of Zantrene.